DynamiCure Doses First Patients in Phase 1 Clinical Trial of Lead Antibody Candidate DCBY02 in Advanced Cancers
November 8, 2022The lead candidate from DynamiCure’s anti-CD93 program, DCBY02 targets a wide range of metastatic solid tumors Phase 1 trial aims to assess the safety and anti-tumor activity of the candidate in dose-escalation and dose-expansion phases of the study Waltham, MA — November 8, 2022 — DynamiCure, a private biopharmaceutical company…
DynamiCure Announces IND Clearance to Advance First Antibody Candidate from its DC-6001 Anti-CD93 Program into Clinical Development
August 22, 2022DCBY02 to be assessed in patients with advanced or metastatic solid tumors across dose-escalation and dose-expansion parts of a Phase 1 clinical study Waltham, MA — August 22, 2022 — DynamiCure, a private biopharmaceutical company translating pioneering immuno-normalization insights into a pipeline of innovative therapeutic antibody candidates, today announced that…